TWiV 1016: Clinical update with Dr. Daniel Griffin
b'
In his weekly clinical update, Dr. Griffin discusses surveillance to track progress toward poliomyelitis eradication, genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3, evaluation of Oseltamivir used to prevent hospitalization in outpatients with Influenza, viral emissions into the air and environment after SARS-CoV-2 human challenge, has COVID-19 threatened routine childhood vaccination, successful treatment of persistent symptomatic COVID-19 infection with extended duration Nirmatrelvir/Ritonavir, anemia as a risk factor for disease progression in patients admitted for COVID-19, impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome, post-COVID condition in patients with inflammatory rheumatic diseases, outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months, metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial, persistent serum protein signatures define an inflammatory subcategory of long COVID, and the relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.
Subscribe (free):\\xa0Apple Podcasts,\\xa0Google Podcasts,\\xa0RSS,\\xa0email
Become a\\xa0patron\\xa0of\\xa0TWiV!
Links for this episode
- Surveillance\\xa0to track progress toward poliomyelitis eradication (CDC)
- Genetic stabilization of\\xa0attenuated oral vaccines\\xa0against poliovirus types 1 and 3 (Nature)
- Evaluation of Oseltamivir to prevent hospitalization in outpatients with\\xa0Influenza\\xa0(JAMA)
- Viral emissions\\xa0into air and environment after SARS-CoV-2 human challenge (The Lancet)
- Has COVID-19 threatened\\xa0routine childhood vaccination\\xa0(Health Affairs)
- Successful treatment\\xa0of COVID-19 with extended duration Nirmatrelvir/Ritonavir (OFID)
- Anemia as a risk factor for disease progression in patients admitted for\\xa0COVID-19\\xa0(Nature)
- Impact of fatigue\\xa0as the determinant of functional limitations among patients with post-COVID-19 syndrome (BMJ)
- Post-COVID condition in patients with\\xa0inflammatory rheumatic diseases\\xa0(The Lancet)
- Outpatient treatment\\xa0of COVID-19 and incidence of post-COVID-19 condition (The Lancet)
- Metformin reduces\\xa0SARS-CoV-2\\xa0in a Phase 3 placebo controlled clinical trial (MedRxiv)
- Persistent serum protein define an inflammatory subcategory of\\xa0long COVID\\xa0(Nature)
- Relevance\\xa0of pacing strategies in managing symptoms of post-COVID-19 syndrome (JTM)
- Contribute to our\\xa0FIMRC fundraiser at PWB
- Letters read\\xa0on TWiV 1016
- Dr. Griffin\\u2019s COVID treatment summary (pdf)
- Timestamps by\\xa0Jolene. Thanks!
Intro music is by\\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
'